The current P/E ratio of CTLT cannot be calculated, as the latest EPS of -$2.29 is negative. The last PE ratio of Catalent, recorded in March 2023, was 547.58.
The PE ratio of Catalent has averaged 57.98 over the last ten years. Analyzing the last ten years, CTLT's PE ratio reached its highest point in the Mar 2023 quarter at 547.58, when the price was $65.71 and the EPS was $0.12. The lowest point was recorded in the Sep 2015 quarter, when it reached 12.21 with a price of $24.3 and an EPS of $1.99.
Maximum annual increase: 64.08% in 2018
Maximum annual decrease: -45.69% in 2021
Year | PE ratio | Change |
---|---|---|
2024 | N/A | N/A |
2023 | N/A | N/A |
2022 | 39.16 | 14.1% |
2021 | 34.32 | -45.69% |
2020 | 63.19 | 7.25% |
2019 | 58.92 | -9.98% |
2018 | 65.45 | 64.08% |
2017 | 39.89 | 54.43% |
2016 | 25.83 | 55.88% |
2015 | 16.57 | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
JAZZ Jazz Pharmaceuticals plc | 16.79 | $7.56B |
SUPN Supernus Pharmaceuticals Inc | 33.17 | $1.98B |
TBPH Theravance Biopharma Inc | N/A | $472.56M |
CTLT Catalent Inc | N/A | $10.83B |
The current price to earnings ratio of CTLT cannot be determined, as its EPS of -$2.29 is negative.
The 3-year average PE ratio for CTLT stock is 119.73.
The 5-year average PE ratio for CTLT stock is 81.28.
Over the last ten years, the quarterly PE ratio reached its highest level at 547.58 in the Mar 2023 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.